Literature DB >> 22383525

Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes.

Jacob M Basak1, Philip B Verghese, Hyejin Yoon, Jungsu Kim, David M Holtzman.   

Abstract

Accumulation of the amyloid β (Aβ) peptide within the brain is hypothesized to be one of the main causes underlying the pathogenic events that occur in Alzheimer disease (AD). Consequently, identifying pathways by which Aβ is cleared from the brain is crucial for better understanding of the disease pathogenesis and developing novel therapeutics. Cellular uptake and degradation by glial cells is one means by which Aβ may be cleared from the brain. In the current study, we demonstrate that modulating levels of the low-density lipoprotein receptor (LDLR), a cell surface receptor that regulates the amount of apolipoprotein E (apoE) in the brain, altered both the uptake and degradation of Aβ by astrocytes. Deletion of LDLR caused a decrease in Aβ uptake, whereas increasing LDLR levels significantly enhanced both the uptake and clearance of Aβ. Increasing LDLR levels also enhanced the cellular degradation of Aβ and facilitated the vesicular transport of Aβ to lysosomes. Despite the fact that LDLR regulated the uptake of apoE by astrocytes, we found that the effect of LDLR on Aβ uptake and clearance occurred in the absence of apoE. Finally, we provide evidence that Aβ can directly bind to LDLR, suggesting that an interaction between LDLR and Aβ could be responsible for LDLR-mediated Aβ uptake. Therefore, these results identify LDLR as a receptor that mediates Aβ uptake and clearance by astrocytes, and provide evidence that increasing glial LDLR levels may promote Aβ degradation within the brain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22383525      PMCID: PMC3340151          DOI: 10.1074/jbc.M111.288746

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

Review 1.  Lipoprotein receptors in the nervous system.

Authors:  Joachim Herz; Hans H Bock
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

2.  Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains.

Authors:  Robert G Nagele; Michael R D'Andrea; H Lee; Venkateswar Venkataraman; Hoau-Yan Wang
Journal:  Brain Res       Date:  2003-05-09       Impact factor: 3.252

3.  Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.

Authors:  Joseph M Castellano; Jungsu Kim; Floy R Stewart; Hong Jiang; Ronald B DeMattos; Bruce W Patterson; Anne M Fagan; John C Morris; Kwasi G Mawuenyega; Carlos Cruchaga; Alison M Goate; Kelly R Bales; Steven M Paul; Randall J Bateman; David M Holtzman
Journal:  Sci Transl Med       Date:  2011-06-29       Impact factor: 17.956

4.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease.

Authors:  K R Bales; T Verina; D J Cummins; Y Du; R C Dodel; J Saura; C E Fishman; C A DeLong; P Piccardo; V Petegnief; B Ghetti; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 5.  Clearing the brain's amyloid cobwebs.

Authors:  D J Selkoe
Journal:  Neuron       Date:  2001-10-25       Impact factor: 17.173

6.  Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the human entorhinal cortex.

Authors:  D R Thal; C Schultz; F Dehghani; H Yamaguchi; H Braak; E Braak
Journal:  Acta Neuropathol       Date:  2000-12       Impact factor: 17.088

7.  Adult mouse astrocytes degrade amyloid-beta in vitro and in situ.

Authors:  Tony Wyss-Coray; John D Loike; Thomas C Brionne; Emily Lu; Roman Anankov; Fengrong Yan; Samuel C Silverstein; Jens Husemann
Journal:  Nat Med       Date:  2003-03-03       Impact factor: 53.440

8.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.

Authors:  Milla Koistinaho; Suizhen Lin; Xin Wu; Michail Esterman; Deanna Koger; Jeffrey Hanson; Richard Higgs; Feng Liu; Seema Malkani; Kelly R Bales; Steven M Paul
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.

Authors:  Ronald B DeMattos; John R Cirrito; Maia Parsadanian; Patrick C May; Mark A O'Dell; Jennie W Taylor; Judith A K Harmony; Bruce J Aronow; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Neuron       Date:  2004-01-22       Impact factor: 17.173

View more
  74 in total

Review 1.  Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.

Authors:  Evan Dorey; Nina Chang; Qing Yan Liu; Ze Yang; Wandong Zhang
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

2.  Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-β clearance in human astrocytes.

Authors:  Lauren K Fong; Max M Yang; Rodrigo Dos Santos Chaves; Sol M Reyna; Vanessa F Langness; Grace Woodruff; Elizabeth A Roberts; Jessica E Young; Lawrence S B Goldstein
Journal:  J Biol Chem       Date:  2018-06-01       Impact factor: 5.157

Review 3.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

4.  ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions.

Authors:  Philip B Verghese; Joseph M Castellano; Kanchan Garai; Yinong Wang; Hong Jiang; Aarti Shah; Guojun Bu; Carl Frieden; David M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-25       Impact factor: 11.205

5.  Relationships of LDLR genetic polymorphisms with cerebral infarction: a meta-analysis.

Authors:  Hai-Cheng Yan; Wei Wang; Chang-Wu Dou; Fu-Ming Tian; Song-Tao Qi
Journal:  Mol Biol Rep       Date:  2014-03-05       Impact factor: 2.316

6.  Apolipoprotein E-low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner.

Authors:  Lance A Johnson; Reid H J Olsen; Louise S Merkens; Andrea DeBarber; Robert D Steiner; Patrick M Sullivan; Nobuyo Maeda; Jacob Raber
Journal:  Neurobiol Dis       Date:  2014-01-09       Impact factor: 5.996

Review 7.  ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?

Authors:  Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

8.  Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration.

Authors:  Magdalena A Kuszczyk; Sandrine Sanchez; Joanna Pankiewicz; Jungsu Kim; Malgorzata Duszczyk; Maitea Guridi; Ayodeji A Asuni; Patrick M Sullivan; David M Holtzman; Martin J Sadowski
Journal:  Am J Pathol       Date:  2013-03-13       Impact factor: 4.307

9.  Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.

Authors:  Hisham Qosa; Bilal S Abuasal; Ignacio A Romero; Babette Weksler; Pierre-Oliver Couraud; Jeffrey N Keller; Amal Kaddoumi
Journal:  Neuropharmacology       Date:  2014-01-24       Impact factor: 5.250

10.  APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.

Authors:  Katherine L Youmans; Leon M Tai; Evelyn Nwabuisi-Heath; Lisa Jungbauer; Takahisa Kanekiyo; Ming Gan; Jungsu Kim; William A Eimer; Steve Estus; G William Rebeck; Edwin J Weeber; Guojun Bu; Chunjiang Yu; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.